Supernus Pharmaceuticals
SUPN
221 hedge funds and large institutions have $1.13B invested in Supernus Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 83 increasing their positions, 94 reducing their positions, and 20 closing their positions.
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
19% more capital invested
Capital invested by funds: $951M → $1.13B (+$184M)
3% more funds holding
Funds holding: 214 → 221 (+7)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
12% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 94
25% less call options, than puts
Call options by funds: $2.17M | Put options by funds: $2.87M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$19.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$7.07M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.57M |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$5.11M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$5.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$18.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.5M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$6.29M |
| 4 |
Millennium Management
New York
|
-$5.3M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$4.95M |
SUPN Hedge Fund Activity: Q3 2016 in Review
221 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2016, worth a combined $1.13B — up 19% from $951M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SUPN positions and 20 closed out — a net gain of 7 holders — while 83 added to existing stakes and 94 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $19.3M. The largest seller was Ranger Investment Management, cutting an estimated $18.7M.
- 221 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2016, up from 214 in Q2 2016.
- Funds reported $1.13B of Supernus Pharmaceuticals stock for Q3 2016, up 19% quarter-over-quarter.
- 27 funds opened new Supernus Pharmaceuticals positions in Q3 2016 and 20 closed out, a net change of +7 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $19.3M added.
- The largest Supernus Pharmaceuticals seller in Q3 2016 was Ranger Investment Management, an estimated $18.7M sold.
Based on aggregated 13F filings for Q3 2016.